Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
G Mining Ventures Posts Lower Q3 Production YoY from Tocantinzinho Gold Mine

G Mining Ventures Posts Lower Q3 Production YoY from Tocantinzinho Gold Mine

MT newswireMT newswire2026/10/08 11:04

07:04 AM EDT, 10/08/2026 (MT Newswires) -- G Mining Ventures (GMIN.TO) reported third-quarter preliminary production of 44,960 ounces of gold, down from 46,360 ounces a year earlier, from the Tocantinzinho Gold Mine in Brazil. G Mining has produced 113,651 ounces of gold year to date, putting it on track to achieve the midpoint of 2026 production guidance of 160,000 to 190,000 ounces, the company said Thursday. G Mining sold 43,110 ounces of gold, down from 49,119 ounces a year ago.

07:04 AM EDT, 10/08/2026 (MT Newswires) -- G Mining Ventures (GMIN.TO) reported third-quarter preliminary production of 44,960 ounces of gold, down from 46,360 ounces a year earlier, from the Tocantinzinho Gold Mine in Brazil. G Mining has produced 113,651 ounces of gold year to date, putting it on track to achieve the midpoint of 2026 production guidance of 160,000 to 190,000 ounces, the company said Thursday. G Mining sold 43,110 ounces of gold, down from 49,119 ounces a year ago.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss